Oslo University Hospital
Oslo, N0310, Norway
Completed
NCT Number: NCT01311466
Liver Transplantation and Uveal Malignant Melanoma
Patients with uveal malignant melanoma with liver metastases have median survival of less than 12 months. There is no established treatment showing increased overall survival. The study will determine if liver transplantation will result in long term survival in patients with liver metastases from uveal malignant melanoma.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Uveal malignant melanoma
- Liver metastases
- ECOG 0-1
Exclusion criteria
- Extra hepatic disease
- Previous other malignancy
- Previous organ transplantation
Treatment and study plan
Liver Transplantation
ProcedurePrimary outcomes
-
Over all survival
Time frame: 1 year
Patient survival after livertransplantation
Sponsors and collaborators
Lead sponsor
Oslo University Hospital
Other
Registry information
Official study title
Open Non-randomized Study to Assess the Benefit of Liver Transplantation in Patients With Liver Metastasis After Ocular Malignant Melanoma (Uveal Melanoma)
Important dates
- Study start
- 2011
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Mar 9, 2011
- Registry last updated
- Oct 23, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.